Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
NuGen Medical Devices Inc
V.NGMD
Alternate Symbol(s):
NGMDF
NuGen Medical Devices Inc. is a Canada-based specialty medical device company. The Company is engaged in marketing and selling its InsuJet needle-free injection system designed to improve the lives of millions of diabetics. Its principal business is the research, development and commercialization of needle-free injection devices and systems for the administration of subcutaneous medication. It is developing products using its needle-free delivery technology in several fields including, but not limited to, diabetes, semaglutide, growth and fertility hormone, as well as deoxyribonucleic acid (DNA) and conventional/pediatric vaccines. It is focusing its development efforts on needle free devices in the area of liquid jet delivery through the InsuJet platform. The Company's InsuJet technology platform is based on jet-stream administration of liquid drugs. The Company manufactures and commercializes needle-free injection systems and sells in over 40 countries globally.
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
New Post
TSXV:NGMD - Post by User
NuGen Medical Devices Inc
> New Press Release - NuGen Medical Commences Feasibility Study, Validation and Testing for Semaglutide - "Ozempic(R)"
<< Previous
Bullboard Posts
Next >>
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 10, 2023 5:16pm
57 Views
Post# 35387429
New Press Release - NuGen Medical Commences Feasibility Study, Validation and Testing for Semaglutide - "Ozempic(R)"
New Press Release - NuGen Medical Commences Feasibility Study, Validation and Testing for Semaglutide - "Ozempic(R)"
Toronto, Ontario--(Newsfile Corp. - April 10, 2023) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") announces it has engaged Basic Pharma Technologies, a pharmaceutical company located in the Netherlands, to perform an assessment and feasibility study, which will include...
read article.
Comment on this Post
<< Previous
Bullboard Posts
Next >>
Why invest?
BioNTech & Cardiol Therapeutics – on the verge of a breakout
Optimi Health to advance psychedelic clinical trials
Two catalysts for investing in tokenized real-world assets
Maximizing savings: Exploring 5 cash-back and promo deal apps
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
{{ dialogTitle }}
×
Reject Reason
{{ policy.description }}
{{reasonError}}
Additional Comments
{{feedbackError}}
{{buttonTitle}}
Cancel
{{submitMsg}}
Featured News Links
LISTEN to the Jetstream #1 HELIUM appraisal well roar! Flow & Pressure Build-Up Tests Commence
This Gambling Tech Stock Might be the Safest Bet you’ll make this Year
Cam Copper Mine: Discovery of Large Near Surface EM Conductor